Genmab combination halves death risk in Phase 3 head-and-neck cancer study
Genmab said its petosemtamab combination halved the risk of death in a Phase 3 study in head-and-neck cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Genmab Combination Halves Death Risk in Phase 3 Head and Neck Cancer Study
Genmab said its petosemtamab combination halved the risk of death in a Phase 3 head and neck cancer study.